Industry / Switzerland
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Actelion Agrees US$3.3bn Licensing Deal With GSK For Insomnia Drug
July 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Swiss biopharmaceuticals firm Actelion has secured a lucrative licensing deal with GlaxoSmithKline (GSK) for its insomnia candidate almorexant. In return for worldwide marketing rights (excluding Japan) to the drug, GSK could fork out as much as US$3.3bn.